GEN Exclusives

More »

GEN News Highlights

More »
May 28, 2009

GE Healthcare to Market Fujifilm Image-Analysis Platforms Worldwide

  • GE Healthcare and Fujifilm signed a strategic alliance to co-develop new biomolecular imaging systems based on Fujifilm’s CCD and laser-based imaging technology, which GE will market under its own brands to the life science research and drug discovery markets worldwide.

    The deal primarily aims to develop application-specific systems and will also allow GE to market Fujifilm's top-spec FLA-9000 and FLA-7000 multipurpose imaging scanners. These will be offered as an extension to its Typhoon family of variable-mode imagers for phosphor and fluorescence applications. Fujifilm’s LAS 4000 platform, a luminescent image analyzer to feature the company’s proprietary CCD technology, will be marketed by GE through its existing ImageQuant product family.

    “Fujifilm’s high-quality technology platforms fit well with our proprietary labeling technologies and the adjacent fields in the imaging workflow that GE Healthcare currently addresses,” comments GE Healthcare’s Nigel Darby, GM of biotechnologies, life sciences.

    Yuzo Toda, director, corporate vp, GM of life science products division at Fujifilm, adds, “GE’s Healthcare’s global presence as a supplier of reagents and instruments and its competence in biological applications within the life science field combined with Fujifilm’s leading imaging technologies, R&D, and manufacturing capabilities will provide our customers with comprehensive system solutions for research, drug discovery, and bioanalytical applications.”

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Easing Restrictions for Terminal Patients

Should the Federal Government Pass a “Right to Try” Bill Allowing Terminally Ill Patients Access to Experimental Medicines?

More »